primary central nervous system lymphoma
Conditions
Interventions
one:Dose density Improved High dose methotrexate (HD-MTX) chemotherapy
Sponsors
Cancer Center, Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients must meet the following criteria for study entry: 1. Aged 18 to 70 years old, ECOG performance status of 0, 1, or 2, Life expectancy of >12 weeks; 2. All patents are diagnosed as Primary central nervous system B cell lymphoma by pathology . Including postoperative patients; 3. Adequate hematologic and hepatic-renal function: Hemoglobin >=9 g/dl, Absolute neutrophil count >=1.5*10^9/L, Platelet count >=100*10^9/L, ALT = 12 months after the last chemotherapy; 6. Ability and willingness to comply with the study protocol.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded from study entry: 1. Patients had previously received other treatment such as chemotherapy or radiotherapy (Not including surgery); 2. Refuse to provide the blood sample; 3. History of severe allergic or anaphylactic reactions to any drugs including the protocol; 4. All patients of reproductive potential refuse to use adequate methods of contraception during the treatment period and until >12 months after the last chemotherapy; 5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease, uncontrolled diabetes mellitus, pulmonary disease or severe hepatic and renal dysfunction; 6. Serious infections; 7. Contraindications of radiotherapy and chemotherapy; 8. History of other malignancy; 9. Mental disorder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response;partial response;Overall Response rate;Grade 3/4 toxicities;Neurocognitive assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-Free Survival; | — |
Countries
China
Contacts
Public ContactWeiping Tao
Renmin Hospital of Wuhan University
Outcome results
None listed